Philogen S.p.a.
Clinical trials sponsored by Philogen S.p.a., explained in plain language.
-
New scan agent shows promise for spotting prostate cancer
Diagnosis CompletedThis study tested a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal was to see if it is safe and how much radiation the body receives. The agent helps doctors see cancer spots that other scans might miss.
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Diagnosis
Last updated May 13, 2026 16:01 UTC
-
New imaging agent shows promise for kidney cancer detection
Diagnosis CompletedThis study tested a new radioactive imaging agent called 68Ga-OncoCAIX in 20 people with clear cell renal cell carcinoma (a type of kidney cancer). The goal was to see if it is safe and how it spreads in the body. Researchers measured radiation doses to organs and checked for sid…
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Diagnosis
Last updated May 12, 2026 13:40 UTC